Evidence map›Paper›PMID 39808162›Full record

ArticleCancer research2025

Evolutionary Pressures Shape Undifferentiated Pleomorphic Sarcoma Development and Radiotherapy Response.

Erik S Blomain, Shaghayegh Soudi, Ziwei Wang, Anish Somani, Ajay Subramanian, Serey C L Nouth, Eniola Oladipo, Christin New, Deborah E Kenney, Neda Nemat-Gorgani and 12 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Erik S BlomainDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-8820-2384
Shaghayegh SoudiDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0009-0009-4678-0798
Ziwei WangDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0002-9994-1331
Anish SomaniDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0009-0002-2568-6638
Ajay SubramanianDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0001-7892-886X
Serey C L NouthDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0009-0007-3075-0223
Eniola OladipoDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0009-0009-8326-4055
Christin NewDepartment of Orthopedic Surgery, Stanford University, Stanford, California.ORCID 0009-0006-9282-2993
Deborah E KenneyDepartment of Orthopedic Surgery, Stanford University, Stanford, California.ORCID 0000-0003-0795-1901
Neda Nemat-GorganiDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0001-9323-8744
Thomas KindlerDepartment of Internal Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0002-0383-0507
Raffi S AvedianDepartment of Orthopedic Surgery, Stanford University, Stanford, California.ORCID 0000-0001-6224-7410
Robert J SteffnerDepartment of Orthopedic Surgery, Stanford University, Stanford, California.ORCID 0000-0003-0405-9520
David G MohlerDepartment of Orthopedic Surgery, Stanford University, Stanford, California.ORCID 0000-0002-8869-139X
Susan M HinikerDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0003-4723-2151
Alexander L ChinDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0003-3785-7799
Anusha KalbasiDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0001-8692-1457
Michael S BinkleyDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0002-2640-5255
Marius FriedDepartment of Internal Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0002-5216-9516
Matthias M GaidaTRON, Translational Oncology at the University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0003-1499-7772
Matt van de RijnDepartment of Pathology, Stanford University, Stanford, California.ORCID 0000-0002-1909-9739
Everett J ModingDepartment of Radiation Oncology, Stanford University, Stanford, California.ORCID 0000-0001-7913-5351

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
My Blue DotsNational Comprehensive Cancer Network Foundation (NCCN Foundation)NCI NIH HHS P30 CA124435Tad and Diane Taube Family Foundation
6 · The paper itself

Abstract

Radiotherapy is an integral component in the treatment of many types of cancer, with approximately half of patients with cancer receiving radiotherapy. Systemic therapy applies pressure that can select for resistant tumor subpopulations, underscoring the importance of understanding how radiation impacts tumor evolution to improve treatment outcomes. We integrated temporal genomic profiling of 120 spatially distinct tumor regions from 20 patients with undifferentiated pleomorphic sarcomas (UPS), longitudinal circulating tumor DNA analysis, and evolutionary biology computational pipelines to study UPS evolution during tumorigenesis and in response to radiotherapy. Most unirradiated UPSs displayed initial linear evolution, followed by subsequent branching evolution with distinct mutational processes during early and late development. Metrics of genetic divergence between regions provided evidence of strong selection pressures during UPS development that further increased during radiotherapy. Subclone abundance changed after radiotherapy with subclone contraction tied to alterations in calcium signaling, and inhibiting calcium transporters radiosensitized sarcoma cells. Finally, circulating tumor DNA analysis accurately measured subclone abundance and enabled noninvasive monitoring of subclonal changes. These results demonstrate that radiation exerts selective pressures on UPSs and suggest that targeting radioresistant subclonal populations could improve outcomes after radiotherapy. Significance: Radiotherapy mediates tumor evolution by leading to the expansion of resistant subclonal cancer cell populations, indicating that developing approaches to target resistant subclones will be crucial to improve radiotherapy response.

Indexed as

SarcomaCirculating Tumor DNAClonal EvolutionEvolution, MolecularFemaleHumansMaleMiddle AgedMutationRadiation ToleranceCirculating Tumor DNA

Identifiers

PMID39808162
PMCPMC13007602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.